RAID Prediction: Pilot Study of Fecal Microbial Signature With Capacity to Predict Response to Anti-TNF Treatment.

Autor:	Busquets D; Servei Aparell Digestiu Hospital Universitari Dr. Josep Trueta, Girona, Spain., Oliver L; GoodGut S.L, Girona, Catalonia, Spain., Amoedo J; GoodGut S.L, Girona, Catalonia, Spain., Ramió-Pujol S; GoodGut S.L, Girona, Catalonia, Spain., Malagón M; GoodGut S.L, Girona, Catalonia, Spain., Serrano M; GoodGut S.L, Girona, Catalonia, Spain., Bahí A; Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Catalonia, Spain., Capdevila M; Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Catalonia, Spain., Lluansí A; Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Catalonia, Spain., Torrealba L; Servei Aparell Digestiu Hospital Universitari Dr. Josep Trueta, Girona, Spain., Peries L; Servei Aparell Digestiu Hospital Universitari Dr. Josep Trueta, Girona, Spain., Chavero R; Servei Aparell Digestiu Hospital Universitari Dr. Josep Trueta, Girona, Spain., Gilabert P; Servei Aparell Digestiu Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain., Sàbat M; Hospital de Santa Caterina, Girona, Catalonia, Spain., Guardiola J; Servei Aparell Digestiu Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain., Serra-Pagès M; GoodGut S.L, Girona, Catalonia, Spain., Garcia-Gil J; GoodGut S.L, Girona, Catalonia, Spain.; Deparment of Biology, University of Girona, Girona, Catalonia, Spain., Aldeguer X; Servei Aparell Digestiu Hospital Universitari Dr. Josep Trueta, Girona, Spain.; GoodGut S.L, Girona, Catalonia, Spain.; Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Catalonia, Spain.
Jazyk:	angličtina
Zdroj:	Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Nov 15; Vol. 27 (Suppl 2), pp. S63-S66.
DOI:	10.1093/ibd/izab273
Abstrakt:	Background and Aims: Crohn's disease and ulcerative colitis evolve with alternate outbreaks and remissions of variable duration in both cases. Despite the advances, about 10-30% of patients do not respond to the treatment after the induction period. Besides, between 20% to 50% further patients need an optimization of the dose to respond the treatment. Recent studies have pointed gut microbiota can play a role in the anti-TNF treatment response. This study aimed to define a bacterial signature that could be used to predict the response of patients to anti-TNF treatment. Methods: There were obtained 38 stool samples from 38 IBD patients before starting anti-TNF treatments: Adalimumab, Golimumab or Infliximab. Patients were differentiated in 2 groups: responders and non-responders to biological treatment. From each sample, DNA was purified and used in a qPCR for the quantification of the 8 microbial markers. Results: In this proof of concept, the predictive ability to identify anti-TNF treatment responders was analyzed. An algorithm consisting in the combination of 4 bacterial markers showed a high capacity to discriminate between responders and non- responders. The algorithm proved high sensitivity and specificity reporting values of 93.33% and 100% respectively, with a positive predictive value of 100% and a negative predictive value of 75% for predicting response to biologic treatment. Conclusions: A specific bacterial signature could beneficiate patients with inflammatory bowel disease predicting the therapeutic effectiveness of an anti-TNF treatment, leading to a personalized therapy, improving the patients' quality of life, saving costs and gaining time in patient improvement. (© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu